Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma. A Multicenter Phase II Trial
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
Price : $35 *
At a glance
- Drugs Nelfinavir (Primary) ; Bortezomib; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 31 May 2018 Status changed from active, no longer recruiting to completed.
- 03 May 2018 Planned End Date changed from 1 Dec 2018 to 1 Aug 2018.